• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Rises; Adobe Posts Upbeat Results

    6/16/23 12:00:30 PM ET
    $ADBE
    $AZRE
    $CHRS
    $CLNN
    Computer Software: Prepackaged Software
    Technology
    Electric Utilities: Central
    Utilities
    Get the next $ADBE alert in real time by email

    U.S. stocks traded slightly higher midway through trading, with Dow Jones gaining around 20 points on Friday.

    The Dow traded up 0.06% to 34,428.13 while the NASDAQ rose 0.05% to 13,789.23. The S&P 500, also rose, gaining, 0.19% to 4,434.03.

    Check This Out: FedEx Likely To Report Lower Q4 Earnings; Here's A Look At Recent Price Target Changes By The Most Accurate Analysts

     

    Leading and Lagging Sectors

    • Utilities shares jumped by 1.1% on Friday. Meanwhile, top gainers in the sector included ReNew Energy Global Plc (NASDAQ:RNW), up 4%, and Azure Power Global Limited (NYSE:AZRE), up 3%.
    • In trading on Friday, materials shares fell by 0.3%.

     

    Top Headline

    Adobe Inc. (NASDAQ:ADBE) reported better-than-expected results for its second quarter and issued strong earnings forecast.

    Adobe said second-quarter revenue increased 10% year-over-year to $4.82 billion, which beat the consensus estimate of $4.43 billion. The creative software company reported quarterly adjusted earnings of $3.91 per share, which beat estimates of $3.79 per share.

    Adobe expects third-quarter revenue to be in the range of $4.83 billion to $4.87 billion versus estimates of $4.86 billion. Third-quarter adjusted earnings are expected to be between $3.95 and $4 per share versus estimates of $3.89 per share.

     

    Equities Trading UP

    • Virgin Galactic Holdings, Inc. (NYSE:SPCE) shares shot up 30% to $5.26 after the company on Thursday said its first commercial spaceflight is planned to fly between June 27 and June 30 and the second will follow in early August.
    • Shares of iRobot Corporation (NASDAQ:IRBT) got a boost, shooting 19% to $50.09 after UK's Competition and Markets Authority cleared its acquisition deal with Amazon.
    • Evelo Biosciences, Inc. (NASDAQ:EVLO) shares were also up, gaining 198% to $0.2471 after the company won U.S. Patent for prebiotic compositions and methods of use thereof for modulation of the microbiome.

     

    Equities Trading DOWN

    • Panbela Therapeutics, Inc. (NASDAQ:PBLA) shares dropped 53% to $2.7366 after the company announced pricing of an approximately $8.5 million public offering,
    • Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) were down 18% to $4.4250. Coherus BioSciences agreed to acquire Surface Oncology Inc (NASDAQ:SURF), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment.
    • Clene Inc. (NASDAQ:CLNN) was down, falling 15% to $0.8898 after the company announced pricing of a $40 million public offering. Clene’s CNM-Au8 treatment demonstrated a statistically significant reduction of plasma neurofilament light chain levels compared to placebo at 24 weeks.

    Also Check This Out: Bitcoin Surpasses This Key Level; Trust Wallet Token Emerges As Top Gainer

     

    Commodities

    In commodity news, oil traded up 0.7% to $71.11 while gold traded down 0.2% at $1,967.40.

    Silver traded up 0.1% to $23.965 on Friday while copper rose 0.1% to $3.9045.

     

    Euro zone

    European shares were higher today. The eurozone’s STOXX 600 rose 0.63%, London’s FTSE 100 rose 0.32% while Spain’s IBEX 35 Index rose 1.02% The German DAX gained 0.5% French CAC 40 climbed 1.33% and Italy’s FTSE MIB Index gained 0.67%.

    The consumer price inflation in the Eurozone came in at 6.1% in May, recording the lowest level since Feb. 2022. Wages and salaries in the Eurozone increased by 4.6% year-over-year in the first quarter, while hourly labor costs rose by 5 % year-over-year. The annual inflation rate in Italy eased to 7.6% in May from 8.2% in the prior month.

     

    Asia Pacific Markets

    Asian markets closed higher on Friday, with Japan’s Nikkei 225 gaining 0.66%, Hong Kong’s Hang Seng Index gaining 1.07% and China’s Shanghai Composite Index gaining 0.63%. India’s S&P BSE Sensex rose 0.8%.

    The Bank of Japan maintained its key short-term interest rate at -0.1% at its June meeting.

     

    Economics

    The University of Michigan consumer sentiment rose to 63.9 in June, recording the highest level in four months, compared to 59.2 in the previous month.

    Now Read This: $3.8M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying

     

    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 107,201,630 cases with around 1,166,890 deaths. India confirmed a total of at least 44,993,280 cases and 531,890 deaths, while France reported over 40,119,160 COVID-19 cases with 167,500 deaths. In total, there were at least 690,387,000 cases of COVID-19 worldwide with more than 6,891,720 deaths.

    Get the next $ADBE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADBE
    $AZRE
    $CHRS
    $CLNN

    CompanyDatePrice TargetRatingAnalyst
    Adobe Inc.
    $ADBE
    2/3/2026$330.00Overweight → Neutral
    Piper Sandler
    Coherus Oncology Inc.
    $CHRS
    1/23/2026$10.00Outperform
    Oppenheimer
    Adobe Inc.
    $ADBE
    1/13/2026Outperform → Perform
    Oppenheimer
    Adobe Inc.
    $ADBE
    1/12/2026$290.00Sell
    Goldman
    Adobe Inc.
    $ADBE
    1/9/2026$375.00Outperform → Market Perform
    BMO Capital Markets
    Adobe Inc.
    $ADBE
    1/5/2026$400.00Buy → Hold
    Jefferies
    Adobe Inc.
    $ADBE
    12/15/2025$310.00Sector Weight → Underweight
    KeyBanc Capital Markets
    Adobe Inc.
    $ADBE
    12/15/2025$405.00 → $400.00Outperform
    BMO Capital Markets
    More analyst ratings

    $ADBE
    $AZRE
    $CHRS
    $CLNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Adobe downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Adobe from Overweight to Neutral and set a new price target of $330.00

    2/3/26 6:51:31 AM ET
    $ADBE
    Computer Software: Prepackaged Software
    Technology

    Oppenheimer initiated coverage on Coherus BioSciences with a new price target

    Oppenheimer initiated coverage of Coherus BioSciences with a rating of Outperform and set a new price target of $10.00

    1/23/26 8:18:28 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adobe downgraded by Oppenheimer

    Oppenheimer downgraded Adobe from Outperform to Perform

    1/13/26 8:59:51 AM ET
    $ADBE
    Computer Software: Prepackaged Software
    Technology

    $ADBE
    $AZRE
    $CHRS
    $CLNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Matlin David J bought $216,664 worth of shares (33,333 units at $6.50), increasing direct ownership by 7% to 477,824 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    1/13/26 2:48:54 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & CFO Durn Daniel bought $507,758 worth of shares (1,300 units at $390.58), increasing direct ownership by 5% to 29,876 units (SEC Form 4)

    4 - ADOBE INC. (0000796343) (Issuer)

    3/21/25 4:34:57 PM ET
    $ADBE
    Computer Software: Prepackaged Software
    Technology

    Director Ricks David A bought $998,946 worth of shares (2,250 units at $443.98) (SEC Form 4)

    4 - ADOBE INC. (0000796343) (Issuer)

    1/30/25 7:45:44 PM ET
    $ADBE
    Computer Software: Prepackaged Software
    Technology

    $ADBE
    $AZRE
    $CHRS
    $CLNN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Adobe Inc.

    SCHEDULE 13G/A - ADOBE INC. (0000796343) (Subject)

    2/5/26 12:23:46 PM ET
    $ADBE
    Computer Software: Prepackaged Software
    Technology

    Coherus Oncology Inc. filed SEC Form 8-K: Other Events

    8-K - Coherus Oncology, Inc. (0001512762) (Filer)

    2/4/26 8:40:28 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Coherus Oncology Inc.

    SCHEDULE 13G/A - Coherus Oncology, Inc. (0001512762) (Subject)

    1/30/26 3:27:59 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADBE
    $AZRE
    $CHRS
    $CLNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ugwumba Chidozie sold $22,792 worth of shares (5,559 units at $4.10) (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    2/5/26 10:18:03 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Ugwumba Chidozie sold $104,862 worth of shares (24,770 units at $4.23) (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    2/2/26 5:10:00 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Ugwumba Chidozie sold $96,045 worth of shares (19,274 units at $4.98) (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    1/28/26 5:01:41 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADBE
    $AZRE
    $CHRS
    $CLNN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks

    Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Jan. 27, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – The global oncology therapy market is charging toward a massive $668 billion valuation by 2034, as a ruthless capital rotation finally rewards execution-ready platforms over the "hopes and dreams" of speculative discovery assets[1]. With the FDA's accelerated approval pathway delivering survival wins across 65% of solid tumor indications, the 2026 regulatory landscape is demanding a new breed of registration-directed study designs that prioritize raw objective response rates and durability[2]. This structural shift creates an asymmetric investment window for Oncolytic

    1/27/26 10:50:00 AM ET
    $CHRS
    $MRK
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Presenting on Emerging Growth Conference 89 Day 2 on January 22; Register to live stream

    MIAMI, Jan. 21, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of Day 2 of the 89th Emerging Growth Conference on January 21 & 22, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - Presenting Today - January 21, 2026 8:45Virtual Lobby opens.Register for the Conference. If you alread

    1/21/26 7:00:00 AM ET
    $CLNN
    $DEVS
    $DGXX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance/Investors Services
    Finance

    Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream

    MIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 89th Emerging Growth Conference on January 21 & 22, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - WednesdayJanuary 21, 2026 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go ba

    1/20/26 7:00:00 AM ET
    $CLNN
    $DEVS
    $DGXX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance/Investors Services
    Finance

    $ADBE
    $AZRE
    $CHRS
    $CLNN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for CIMERLI issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug CIMERLI (SUPPL-5) with active ingredient RANIBIZUMAB-EQRN has changed to 'Approval' on 05/21/2024. Application Category: BLA, Application Number: 761165, Application Classification:

    5/22/24 9:41:01 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for LOQTORZI issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug LOQTORZI (SUPPL-1) with active ingredient TORIPALIMAB-TPZI has changed to 'Approval' on 04/22/2024. Application Category: BLA, Application Number: 761240, Application Classification:

    4/23/24 4:41:07 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for UDENYCA issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug UDENYCA (SUPPL-15) with active ingredient PEGFILGRASTIM-CBQV has changed to 'Approval' on 12/22/2023. Application Category: BLA, Application Number: 761039, Application Classification:

    12/27/23 4:38:39 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADBE
    $AZRE
    $CHRS
    $CLNN
    Leadership Updates

    Live Leadership Updates

    View All

    SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer

    ALISO VIEJO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a late-stage biopharmaceutical company, today announced the appointment of Jean-Frédéric Viret, Ph.D., as the company's Chief Financial Officer (CFO). Dr. Viret brings over two decades of corporate finance experience in the life sciences industry, leading companies from early-stage clinical development through post-commercialization. At SpyGlass, he will lead the finance and accounting functions as the company advances the Bimatoprost Drug Pad-IOL System (BIM-IOL System) toward late-stage development and potential commercialization. "We are excited to welcome Jean to SpyGlass Pharma as we continue to advance our clin

    1/6/26 8:00:00 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

    – Responsible for Corporate Development, Investor Relations, Government Affairs – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that Arvind Sood has joined the Company as Chief Strategy and Corporate Affairs Officer reporting to Denny Lanfear, Chairman and Chief Executive Officer. Mr. Sood's responsibilities include key externally facing and strategic functions. "We are thrilled to have a such a well-regarded senior biotechnology executive join us as we advance our innovative, next generation cancer therapeutics and drive LOQTORZI® revenues in nasopharyngeal carcinoma," said Denny Lanfear, Coherus Oncology Chairman and Chief

    11/6/25 1:54:45 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adobe Delivers New AI Innovations, Assistants and Models Across Creative Cloud to Empower Creative Professionals

    Adobe delivers new AI innovations and industry's top AI models across Creative Cloud apps – including Photoshop, Lightroom, Premiere and Illustrator – empowering creative professionals to save time, meet the rising demand for creative content and work with greater power, precision and control. New AI Assistant in Photoshop, powered by agentic AI, enables creative professionals to scale their work and free up time by instructing the assistant to help on a series of repetitive tasks and surface personalized recommendations, all while maintaining creative control. New AI-powered capabilities in Firefly Boards, including image upscaling and prompt generation, empower creative teams to mo

    10/28/25 8:11:00 AM ET
    $ADBE
    Computer Software: Prepackaged Software
    Technology

    $ADBE
    $AZRE
    $CHRS
    $CLNN
    Financials

    Live finance-specific insights

    View All

    Adobe Reports Record Q4 and FY2025 Revenue

    Exceeds target for FY2025 Digital Media ending ARR and targets FY2026 Total Adobe ending ARR to grow over 10% Delivers record operating cash flows of over $10 billion in FY2025 Adobe (NASDAQ:ADBE), the global technology leader that unleashes creativity and productivity for individuals and businesses through innovative platforms and tools, today reported financial results for its fourth quarter and FY2025 ended Nov. 28, 2025. "Adobe's record FY2025 results reflect our growing importance in the global AI ecosystem and the rapid adoption of our AI-driven tools," said Shantanu Narayen, chair and CEO, Adobe. "By advancing our innovative generative and agentic platforms and expanding our cu

    12/10/25 4:05:00 PM ET
    $ADBE
    Computer Software: Prepackaged Software
    Technology

    Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®

    FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8Biomarker improvements are strongly associated with longer survival, reinforcing CNM-Au8's potential disease modifying activityCompany has requested a Type C meeting in the first quarter of 2026 to present the newly completed analyses supporting a planned NDA submission under the accelerated approval pathwayClene is hosting an investor webcast today at 8:30 am ET SALT LAKE CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene" or the "Company") and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinic

    12/3/25 8:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adobe to Announce Q4 & FY2025 Earnings Results on December 10, 2025

    Today, Adobe (NASDAQ:ADBE) announced it will release its fourth quarter and fiscal year 2025 results after the market closes on Wednesday, Dec. 10, 2025, followed by a conference call with investors from 2-3 p.m. Pacific Time. The conference call will be streamed live on the Adobe Investor Relations Site. Following the call, a recording and related materials will be available on the site. Adobe uses its website as a channel of distribution of material company information. Financial, product and other material information regarding the company is routinely posted on and accessible at www.adobe.com/ADBE. About Adobe Adobe is changing the world through digital experiences. For more informat

    12/1/25 1:00:00 PM ET
    $ADBE
    Computer Software: Prepackaged Software
    Technology

    $ADBE
    $AZRE
    $CHRS
    $CLNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ReNew Energy Global plc

    SC 13D/A - ReNew Energy Global plc (0001848763) (Subject)

    12/10/24 7:57:27 PM ET
    $RNW
    Electric Utilities: Central
    Utilities

    Amendment: SEC Form SC 13D/A filed by ReNew Energy Global plc

    SC 13D/A - ReNew Energy Global plc (0001848763) (Subject)

    12/10/24 7:53:40 PM ET
    $RNW
    Electric Utilities: Central
    Utilities

    Amendment: SEC Form SC 13D/A filed by ReNew Energy Global plc

    SC 13D/A - ReNew Energy Global plc (0001848763) (Subject)

    12/10/24 7:32:48 PM ET
    $RNW
    Electric Utilities: Central
    Utilities